Skip to content

Study · Not a test of the peptide alone · 1990

3 results

Effects of calcitonin on GH response to pyridostigmine in combination with hGHRH (1-29) NH2 in normal adult subjects.

Giustina A, Bodini C, Bossoni S, Doga M, Girelli A, Pizzocolo G, Wehrenberg WB

Clinical endocrinology1 Sept 1990Cited by 6 (Europe PMC)

PMID2147598 (opens in a new tab)DOI10.1111/j.1365-2265.1990.tb00502.x (opens in a new tab)PepBankPUB-02147598
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01HumanNot a test of Sermorelin aloneNon-randomized trialMechanism

    In normal adults, prior salmon calcitonin significantly suppressed the GH response to human GHRH (1-29) NH2.

    In plain wordsIn healthy adults, calcitonin given first reduced the growth hormone response to GHRH.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH response to GHRH after salmon calcitonin
    Study

    n: not reported in source

    Comparator
    GHRH without calcitonin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The GH response to GHRH was significantly suppressed by prior administration of sCT.
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the mechanism of the inhibitory action of sCT on the GH response to human GHRH (1-29) NH2 by concomitant PD administration in normal humans.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02HumanNot a test of Sermorelin aloneNon-randomized trialMechanism

    In normal adults, pyridostigmine pretreatment significantly enhanced the GH response to GHRH.

    In plain wordsIn healthy adults, pyridostigmine given first increased the growth hormone response to GHRH.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response to GHRH after pyridostigmine
    Study

    n: not reported in source

    Comparator
    GHRH without pyridostigmine
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Pretreatment of subjects with PD significantly enhanced the GH response to GHRH
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the mechanism of the inhibitory action of sCT on the GH response to human GHRH (1-29) NH2 by concomitant PD administration in normal humans.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03HumanNot a test of Sermorelin aloneNon-randomized trialMechanism

    In normal adults, pyridostigmine pretreatment did not alter the inhibitory action of salmon calcitonin on the GH response to GHRH.

    In plain wordsIn healthy adults, pyridostigmine did not change how calcitonin reduced the growth hormone response to GHRH.

    Peptide
    Sermorelin
    Outcome
    No significant changeCalcitonin inhibition of GH response after pyridostigmine
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    but did not alter the inhibitory actions of sCT.
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the mechanism of the inhibitory action of sCT on the GH response to human GHRH (1-29) NH2 by concomitant PD administration in normal humans.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    10 Oct 2026, 10:21 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.